Calidi Biotherapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Calidi Biotherapeutics CEO'su Allan Camaisa, Feb2018 tarihinde atandı, in görev süresi 6.83 yıldır. in toplam yıllık tazminatı $ 436.51K olup, şirket hissesi ve opsiyonları dahil olmak üzere 58.9% maaş ve 41.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.4% ine doğrudan sahiptir ve bu hisseler $ 162.63K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.8 yıl ve 3.9 yıldır.

Anahtar bilgiler

Allan Camaisa

İcra Kurulu Başkanı

US$436.5k

Toplam tazminat

CEO maaş yüzdesi	58.9%
CEO görev süresi	6.8yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	6.8yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Allan Camaisa'un ücretlendirmesi Calidi Biotherapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$437k	US$257k	-US$29m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$24m
Dec 31 2022	US$2m	US$43k	-US$25m
Sep 30 2022	n/a	n/a	-US$21m
Dec 31 2021	US$1m	US$26k	-US$11m

Tazminat ve Piyasa: Allan 'nin toplam tazminatı ($USD 436.51K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 641.60K ).

Tazminat ve Kazançlar: Allan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Allan Camaisa (64 yo)

6.8yrs

Görev süresi

US$436,512

Tazminat

Mr. Allan J. Camaisa serves as Chief Executive Officer and Chairman of the Board at Calidi Biotherapeutics, Inc since February 2018. He served as Chief Executive Officer and Chairman at Parallel 6, Inc. si...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 162.6k
Wendy Pizarro Campbell	Chief Administrative Officer	3.3yrs	US$295.40k	0.084% $ 34.4k
Boris Minev	President of Medical & Scientific Affairs and Interim Chief Medical Officer	9.5yrs	US$400.10k	0.22% $ 90.0k
Andrew Jackson	Chief Financial Officer	1.2yrs	Veri yok	Veri yok
Stephen Thesing	Chief Business Officer	8.9yrs	Veri yok	0.24% $ 100.0k

6.8yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: CLDI 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 162.6k
James Schoeneck	Independent Director	4.4yrs	US$109.56k	0.53% $ 216.8k
W.K. Yung	Member of Medical Advisory Board	2.5yrs	Veri yok	Veri yok
Ewa Carrier	Member of Medical Advisory Board	no data	Veri yok	Veri yok
George Peoples	Independent Director	less than a year	Veri yok	0.00089% $ 364.5
Scott Leftwich	Independent Vice-Chairman of the Board	5.6yrs	US$179.89k	1.23% $ 504.3k
Alan Stewart	Independent Director	1.2yrs	US$120.56k	0.029% $ 11.7k
Santosh Kesari	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Dmitriy Zamarin	Member of Scientific Advisory Board	3.9yrs	Veri yok	Veri yok
Ashok Srivastava	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Karen Aboody	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Maciej Lesniak	Member of Medical Advisory Board	no data	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CLDI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Calidi Biotherapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Recent updates

Calidi Biotherapeutics Inc. Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.499999 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Less than half of directors are independent

Calidi Biotherapeutics Announces Directorate Changes

Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board

New major risk - Financial position

New major risk - Shareholder dilution

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer

Less than half of directors are independent

Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. announced that it has received funding from Jackson Investment Group, Calidi Cure, LLC

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş